Focused On-demand Library for 26S proteasome regulatory subunit 4

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our top-notch dedicated system is used to design specialised libraries.

Fig. 1. The sreening workflow of Receptor.AI

By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.

Our library stands out due to several important features:

The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.
Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.
Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.
Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.

partner

Reaxense

upacc

P62191

UPID:

PRS4_HUMAN

Alternative names:

26S proteasome AAA-ATPase subunit RPT2; Proteasome 26S subunit ATPase 1

Alternative UPACC:

P62191; B4DR63; P49014; Q03527; Q6IAW0; Q6NW36; Q96AZ3

Background:

The 26S proteasome regulatory subunit 4, also known as PSMC1, plays a crucial role in cellular homeostasis. It is a component of the 26S proteasome, a complex essential for the ATP-dependent degradation of ubiquitinated proteins. This process is vital for removing misfolded or damaged proteins and those no longer needed, thereby participating in cell cycle progression, apoptosis, and DNA damage repair.

Therapeutic significance:

The association of PSMC1 with the neurodevelopmental disorder characterized by poor growth, spastic tetraplegia, and hearing loss highlights its potential as a therapeutic target. Understanding the role of PSMC1 could open doors to potential therapeutic strategies for this and related disorders.